Literature DB >> 21691310

The therapeutic potential of ischemic conditioning: an update.

Derek J Hausenloy1, Derek M Yellon.   

Abstract

Novel approaches are required to improve clinical outcomes in patients with coronary heart disease (CHD). Ischemic conditioning--the practice of applying brief episodes of nonlethal ischemia and reperfusion to confer protection against a sustained episode of lethal ischemia and reperfusion injury--is one potential therapeutic strategy. Importantly, the protective stimulus can be applied before (ischemic preconditioning) or after (ischemic perconditioning) onset of the sustained episode of lethal ischemia, or even at the onset of myocardial reperfusion (ischemic postconditioning). Furthermore, the protective stimulus can be applied noninvasively by placing a blood-pressure cuff on an upper or lower limb to induce brief episodes of nonlethal ischemia and reperfusion (remote ischemic conditioning), a finding that has greatly facilitated the translation of ischemic conditioning to various clinical settings. In addition to mechanical approaches, elucidation of the signal-transduction pathways underlying ischemic conditioning has identified several novel targets for pharmacological conditioning. This Review highlights findings from proof-of-concept clinical studies conducted in the past 5-6 years, in which the therapeutic potential of ischemic and pharmacological conditioning has been realized. Large, randomized, controlled trials are now required to determine whether pharmacological and ischemic conditioning improve clinical end points and outcomes in patients with CHD.

Entities:  

Mesh:

Year:  2011        PMID: 21691310     DOI: 10.1038/nrcardio.2011.85

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  97 in total

1.  Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit.

Authors:  Y Birnbaum; S L Hale; R A Kloner
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

2.  Postconditioning for protection of the infarcting heart.

Authors:  Derek M Yellon; Lionel H Opie
Journal:  Lancet       Date:  2006-02-11       Impact factor: 79.321

3.  Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning.

Authors:  M R Schmidt; M Smerup; I E Konstantinov; M Shimizu; J Li; M Cheung; P A White; S B Kristiansen; K Sorensen; V Dzavik; A N Redington; R K Kharbanda
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-12-15       Impact factor: 4.733

Review 4.  Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

Authors:  Michel Ovize; Gary F Baxter; Fabio Di Lisa; Péter Ferdinandy; David Garcia-Dorado; Derek J Hausenloy; Gerd Heusch; Jakob Vinten-Johansen; Derek M Yellon; Rainer Schulz
Journal:  Cardiovasc Res       Date:  2010-05-06       Impact factor: 10.787

5.  Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.

Authors:  Hans Erik Bøtker; Rajesh Kharbanda; Michael R Schmidt; Morten Bøttcher; Anne K Kaltoft; Christian J Terkelsen; Kim Munk; Niels H Andersen; Troels M Hansen; Sven Trautner; Jens Flensted Lassen; Evald Høj Christiansen; Lars R Krusell; Steen D Kristensen; Leif Thuesen; Søren S Nielsen; Michael Rehling; Henrik Toft Sørensen; Andrew N Redington; Torsten T Nielsen
Journal:  Lancet       Date:  2010-02-27       Impact factor: 79.321

6.  A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study.

Authors:  Erik Lipsic; Peter van der Meer; Adriaan A Voors; B Daan Westenbrink; Ad F M van den Heuvel; Hetty C de Boer; Anton J van Zonneveld; Regien G Schoemaker; Wiek H van Gilst; Felix Zijlstra; Dirk J van Veldhuisen
Journal:  Cardiovasc Drugs Ther       Date:  2006-04       Impact factor: 3.727

7.  Limb ischemic preconditioning reduces heart and lung injury after an open heart operation in infants.

Authors:  Wenwu Zhou; Debing Zeng; Renwei Chen; Jian Liu; Guangxian Yang; Pingbo Liu; Xinmin Zhou
Journal:  Pediatr Cardiol       Date:  2009-09-29       Impact factor: 1.655

Review 8.  Why do we still not have cardioprotective drugs?

Authors:  James M Downey; Michael V Cohen
Journal:  Circ J       Date:  2009-06-09       Impact factor: 2.993

Review 9.  Signaling pathways in ischemic preconditioning.

Authors:  James M Downey; Amanda M Davis; Michael V Cohen
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

Review 10.  Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.

Authors:  Peter Ferdinandy; Rainer Schulz; Gary F Baxter
Journal:  Pharmacol Rev       Date:  2007-11-29       Impact factor: 25.468

View more
  84 in total

Review 1.  Physiology of potassium channels in the inner membrane of mitochondria.

Authors:  Ildikò Szabò; Luigi Leanza; Erich Gulbins; Mario Zoratti
Journal:  Pflugers Arch       Date:  2011-11-18       Impact factor: 3.657

Review 2.  New strategies to optimize kidney recovery and preservation in transplantation.

Authors:  Delphine Bon; Nicolas Chatauret; Sébastien Giraud; Raphael Thuillier; Frédéric Favreau; Thierry Hauet
Journal:  Nat Rev Nephrol       Date:  2012-05-01       Impact factor: 28.314

3.  Endogenous cardioprotection by ischaemic postconditioning and remote conditioning.

Authors:  Weiwei Shi; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2012-02-09       Impact factor: 10.787

4.  Evolving possible link between PI3K and NO pathways in neuroprotective mechanism of ischemic postconditioning in mice.

Authors:  Puja Gulati; Nirmal Singh
Journal:  Mol Cell Biochem       Date:  2014-08-24       Impact factor: 3.396

5.  Serum from patients undergoing remote ischemic preconditioning protects cultured human intestinal cells from hypoxia-induced damage: involvement of matrixmetalloproteinase-2 and -9.

Authors:  Karina Zitta; Patrick Meybohm; Berthold Bein; Christin Heinrich; Jochen Renner; Jochen Cremer; Markus Steinfath; Jens Scholz; Martin Albrecht
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 6.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

7.  "Smoker's Paradox" in Patients Treated for Severe Injuries: Lower Risk of Mortality After Trauma Observed in Current Smokers.

Authors:  Teresa M Bell; Demetria R Bayt; Ben L Zarzaur
Journal:  Nicotine Tob Res       Date:  2015-02-02       Impact factor: 4.244

8.  Involvement of glycogen synthase kinase-3β in liver ischemic conditioning induced cardioprotection against myocardial ischemia and reperfusion injury in rats.

Authors:  Shuai Yang; Geoffrey W Abbott; Wei Dong Gao; Jin Liu; Chaozhi Luo; Zhaoyang Hu
Journal:  J Appl Physiol (1985)       Date:  2017-02-02

Review 9.  Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release.

Authors:  Dmitry B Zorov; Magdalena Juhaszova; Steven J Sollott
Journal:  Physiol Rev       Date:  2014-07       Impact factor: 37.312

10.  Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.

Authors:  Michalis Mastri; Zaeem Shah; Terence McLaughlin; Christopher J Greene; Leah Baum; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Cell Physiol       Date:  2012-07-25       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.